KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizationAmortizationCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in CashChange in IntangiblesChange in IntangiblesDivestmentsDividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShares IssuedShares RepurchasedShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gsk (GSK) Capital Expenditures (2016 - 2026)

Gsk has reported Capital Expenditures over the past 18 years, most recently at -$297.9 million for Q1 2026.

  • For Q1 2026, Capital Expenditures fell 13.73% year-over-year to -$297.9 million; the TTM value through Mar 2026 reached -$1.8 billion, down 4.81%, while the annual FY2025 figure was $1.8 billion, 0.14% changed from the prior year.
  • Capital Expenditures for Q1 2026 was -$297.9 million at Gsk, up from -$762.2 million in the prior quarter.
  • Over five years, Capital Expenditures peaked at $3.2 billion in Q4 2022 and troughed at -$1.6 billion in Q4 2023.
  • A 5-year average of -$243.1 million and a median of -$356.0 million in 2023 define the central range for Capital Expenditures.
  • Biggest five-year swings in Capital Expenditures: soared 352.24% in 2022 and later plummeted 150.49% in 2023.
  • Year by year, Capital Expenditures stood at $3.2 billion in 2022, then plummeted by 150.49% to -$1.6 billion in 2023, then soared by 57.19% to -$698.2 million in 2024, then dropped by 9.16% to -$762.2 million in 2025, then soared by 60.91% to -$297.9 million in 2026.
  • Business Quant data shows Capital Expenditures for GSK at -$297.9 million in Q1 2026, -$762.2 million in Q4 2025, and -$419.7 million in Q3 2025.